{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:34:20Z","timestamp":1790746460524,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.beha.2019.101097","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T01:57:06Z","timestamp":1571363826000},"page":"101097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies"],"prefix":"10.1016","volume":"32","author":[{"given":"Mathew L.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2019.101097_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10147-016-1045-2","article-title":"T-cell lymphomas, a challenging disease: types, treatments, and future","volume":"22","author":"Ma","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.beha.2019.101097_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/gcc.22416","article-title":"Pediatric T-cell acute lymphoblastic leukemia","volume":"56","author":"Karrman","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.beha.2019.101097_bib3","series-title":"Acute leukemias. Hematologic malignancies","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-540-72304-2_13","article-title":"Treatment of adult ALL according to protocols of the German multicenter study group for adult ALL (GMALL)","author":"G\u00f6kbuget","year":"2008"},{"key":"10.1016\/j.beha.2019.101097_bib4","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101097_bib5","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","article-title":"Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience","volume":"21","author":"Goldberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.101097_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","article-title":"How I treat T-cell acute lymphoblastic leukemia in adults","volume":"126","author":"Litzow","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101097_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.beha.2019.101097_bib8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.101097_bib9","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101097_bib10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3324\/haematol.2008.004150","article-title":"T-cell acute lymphoblastic leukemia","volume":"94","author":"Chiaretti","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2019.101097_bib11","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.bbmt.2015.08.023","article-title":"Transplant outcomes for children with T cell acute lymphoblastic leukemia in second remission: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Burke","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2019.101097_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.12862","article-title":"Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia","volume":"98","author":"Thota","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2019.101097_bib13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.101097_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101097_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrd4252","article-title":"Therapeutic modulation of Notch signalling--are we there yet?","volume":"13","author":"Andersson","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.beha.2019.101097_bib16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1078-0432.CCR-16-2825","article-title":"Beating the clock in T-cell acute lymphoblastic leukemia","volume":"23","author":"Carroll","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2019.101097_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-1759(00)00228-3","article-title":"Immunophenotyping of leukemia","volume":"243","author":"Campana","year":"2000","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.beha.2019.101097_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/ajcp\/111.4.467","article-title":"Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases","volume":"111","author":"Khalidi","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.beha.2019.101097_bib19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjh.12042","article-title":"The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report","volume":"159","author":"Patel","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.101097_bib20","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1182\/blood-2009-04-216374","article-title":"Functionally distinct subsets of human NK cells and monocyte\/DC-like cells identified by coexpression of CD56, CD7, and CD4","volume":"114","author":"Milush","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101097_bib21","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \"off-the-shelf\" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2019.101097_bib22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/mt.2015.197","article-title":"Evaluation of TCR gene editing achieved by TALENs, CRISPR\/Cas9, and megaTAL nucleases","volume":"24","author":"Osborn","year":"2016","journal-title":"Mol Ther"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619300866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619300866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:07Z","timestamp":1761498307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692619300866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1521692619300866"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.101097","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.101097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101097"}}